RPAP1 Inhibitors
RPAP1 Inhibitors are an array of chemical compounds that indirectly diminish the functional activity of RPAP1, a protein implicated in the assembly and function of RNA polymerase II. For instance, Palbociclib, a CDK4/6 inhibitor, enforces a cell cycle arrest at the G1 phase, which could lead to a reduced need for RPAP1's role in transcription due to diminished proliferation signals. Similarly, Trichostatin A and Sodium butyrate, both histone deacetylase inhibitors, alter the chromatin structure through increased histone acetylation, which can consequently affect the transcriptional demand and hence, RPAP1 activity. Proteasome inhibitors like MG132 and Bortezomib disrupt protein homeostasis, potentially decreasing RPAP1 activity by inducing cellular stress responses that modify transcriptional requisites. Inhibition of key signaling pathways by compounds such as LY294002 and U0126, which target the PI3K/AKT/mTOR and MEK/ERK pathways respectively, leads to a downregulation of cellular growth processes, indirectly impacting RPAP1 by reducing thegeneral transcriptional and translational needs within the cell.
The biochemical landscape of RPAP1 activity can be further influenced by inhibitors that directly target the transcription and translation machinery. Actinomycin D, an RNA polymerase inhibitor, directly impedes RNA synthesis, thereby restricting RPAP1 function due to the blockade of RNA polymerase II elongation. Cycloheximide's interference with the translocation step of protein synthesis leads to a broad reduction in protein synthesis, affecting various proteins including RPAP1. Additionally, DNA methyltransferase and DNA synthesis inhibitors such as 5-Azacytidine and Mitomycin C play roles in modifying gene expression patterns and DNA replication, which can lead to a subsequent decrease in RPAP1 activity as the cellular machinery adjusts to the altered transcriptional landscape. Through these multifaceted biochemical interactions, each inhibitor contributes to the collective downregulation of RPAP1, illustrating the complexity of cellular control mechanisms and the indirect modulation of specific proteins by targeting associated pathways and processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor that leads to cell cycle arrest in G1 phase. By halting cell cycle progression, the expression and activity of RPAP1, which is involved in RNA polymerase II assembly, may be indirectly reduced due to decreased cellular proliferation requirements. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that leads to increased acetylation of histones, which affects transcription. As RPAP1 is implicated in the transcriptional machinery, the altered chromatin structure may indirectly reduce RPAP1 activity due to changes in transcriptional needs. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Accumulation of proteins may disrupt various cellular processes, potentially leading to a decrease in RPAP1 activity as a response to cellular stress and dysregulated protein homeostasis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that disrupts the PI3K/AKT/mTOR signaling pathway, which is crucial for cell growth and survival. Inhibition of this pathway can lead to reduced protein synthesis and cell proliferation, which may indirectly decrease RPAP1 function due to lowered transcriptional and translational demand. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that suppresses cell growth and proliferation by inhibiting the mTORC1 complex. Since RPAP1 is involved in transcriptional regulation, the general downregulation of transcription and translation processes may reduce RPAP1 activity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that induces hypomethylation of DNA. This can modulate gene expression profiles, potentially leading to a downregulation of RPAP1 due to shifts in cellular transcriptional needs. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
An inhibitor of RNA polymerase that blocks the elongation phase of RNA synthesis. As RPAP1 is involved with RNA polymerase II, the inhibition of RNA synthesis can result in decreased RPAP1 activity due to the direct blocking of its associated process. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
An inhibitor of eukaryotic protein synthesis by interfering with the translocation step in protein synthesis. Reduced protein synthesis may decrease RPAP1 activity as part of a broader reduction in cellular transcriptional and translational demand. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
An alkylating agent that forms crosslinks in DNA, inhibiting DNA synthesis. This can indirectly affect RPAP1 activity by reducing the overall need for transcriptional machinery due to inhibited cell cycle progression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to cell cycle arrest and apoptosis. The disruption of normal proteostasis can indirectly decrease RPAP1 activity as the cell diverts resources to manage protein aggregation and cellular stress. | ||||||